A Study of hTERT/Survivin Multi-Peptide Vaccination With Basiliximab And Prevnar For Patients With Metastatic Breast Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs HTERT-survivin peptide vaccine (Primary) ; Basiliximab; Granulocyte macrophage colony stimulating factor; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Breast cancer
- Focus Adverse reactions
- 25 Jun 2019 Biomarkers information updated
- 06 Feb 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.